Myeloma Trial, Recruiting NCT07445438 Sponsor: Azienda Ospedaliero-Universitaria di Parma Condition: Myeloma
Back to Myeloma

Myeloma Trial, Recruiting

NCT07445438
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are older than 2 years of age
  • People who were previously diagnosed with a blood cancer or blood disorder (for the part of the study looking at past cases)
  • People where doctors suspect a blood cancer or blood disorder and need to run tests using samples such as bone marrow, blood, lymph node tissue, fluid from around the spine, or fluid from around the lungs (for the part of the study looking at new cases)
  • People where doctors suspect a blood cancer or blood disorder that has come back or stopped responding to treatment, and who need testing using bone marrow, blood, lymph node tissue, spinal fluid, or other tissue samples
  • People where doctors suspect a long-term blood condition has progressed to a more serious stage, and who need testing using bone marrow, blood, lymph node tissue, spinal fluid, or other tissue samples

Who may not be able to join:

  • People who are 2 years of age or younger
  • People who do not have a confirmed or suspected diagnosis of a blood cancer or blood disorder

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 15 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: +39 0521 702200

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Azienda Ospedaliero-Universitaria di Parma
Registry
ClinicalTrials.gov
Start date
31 March 2025
Est. completion
1 March 2030

Where this trial is recruiting

🇮🇹 Italy

Primary endpoints

Characterize multi-omics features of different hematological malignancies to identify disease biomarkers; Evaluate the anti-cancer activity of bioactive compounds and derivatives for functionally pharmacotyping the disease and build a nationally oriented multicenter DRP platform.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov